Druggio Logo

Druggio

Insomnia

Insomnia is a common disorder with a prevalence of about 10% in the general population. The most common complaints related to insomnia are difficulty initiating sleep (sleep-onset insomnia), difficulty maintaining sleep due to prolonged nocturnal awakenings (sleep-maintenance insomnia), early morning awakenings, and excessive daytime sleepiness resulting from lack of sleep. Furthermore, insomnia is associated with an increased risk of anxiety and depression, suicidality, and cardiovascular diseases. Currently, cognitive behavioral therapy for insomnia (CBT-I) is recommended as first-line therapy. While behavioral therapies are effective for chronic insomnia in some patients, pharmacotherapy is frequently used when immediate short-term symptom relief is needed. The most effective pharmacologic therapies for insomnia are benzodiazepines, benzodiazepine-receptor agonists, melatonin-receptor agonists, and antidepressants.

Drugs that treat Insomnia

Dayvigo

Made by

Eisai

Approval date

2020/1/23

Treats

Belsomra

Made by

MSD

Approval date

2014/9/26

Treats

Lunesta

Made by

Eisai

Approval date

2012/1/18

Treats

Rozerem

Made by

Takeda

Approval date

2010/4/16

Treats

Myslee

Approval date

2000/9/22

Treats